Upadacitinib ‘safe and tolerable’ in teens with eczema
Researchers have collated safety data for adults and adolescents involved in ongoing trials of the agent
Upadacitinib is an effective and tolerable treatment for moderate-to-severe eczema for out to a year, according to integrated safety data from all phase III studies to date.
International researchers say their findings from the manufacturer-funded studies are consistent with safety data from previously published reports and support the use of both 15mg and 30mg doses in teenagers and adults.
